MCM
PCRX icon

Moore Capital Management’s Pacira BioSciences PCRX Stock Holding History

Moore Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-55,000
Closed -$2.2M – 572
2023
Q2 		$2.2M Buy
+55,000
New +$2.27M 0.04% 246

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Moore Capital Management's PCRX Position: Q3 2023 in Review

Moore Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 55,000 shares — an estimated $2.2M sold.

Moore Capital Management first reported a position in PCRX in Q2 2023 and held it in 1 quarter. The position peaked at $2.2M in Q2 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • Moore Capital Management reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
  • Moore Capital Management sold 55,000 Pacira BioSciences shares in Q3 2023, an estimated $2.2M.
  • Moore Capital Management first reported a position in Pacira BioSciences in Q2 2023 and held it in 1 quarter.
  • Moore Capital Management's Pacira BioSciences position peaked at $2.2M in Q2 2023.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.